"Tule turvallisesti paikan päälle tai asioi etänä. Varaa aika verkkosivuiltamme tai asiakaspalvelun kautta numerosta 030 6000. Ajanvaraus on auki vuorokauden ympäri. Koko Suomen kattavaa toimipaikkaverkostoa täydentävät ympäri vuorokauden saatavilla olevat digitaaliset etäpalvelut. Lääkäri-chat päivystää ilman ajanvarausta 24/7. Voit myös varata ajan video- tai puhelinvastaanotolle valitsemallesi asiantuntijalle. Nopeasti hyvään hoitoon!"

During the past decade, Terveystalo Tampere conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 7 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Terveystalo Tampere" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Pfizer" with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "H. Lundbeck A/S" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Terveystalo Tampere" #1 collaborator was "FGK Clinical Research GmbH" with 1 trials as a collaborator, "Kuopio University Hospital" with 1 trials as a collaborator, "Oulu University Hospital" with 1 trials as a collaborator, "Tampere University Hospital" with 1 trials as a collaborator and "Terveystalo" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Terveystalo Tampere" are "Alzheimer's Disease" (2 trials), "Psoriasis" (2 trials), "Atherosclerotic Cardiovascular Disease" (1 trials), "Atopic Dermatitis" (1 trials) and "Bronchiolitis; Obstruction" (1 trials). Many other conditions were trialed in "Terveystalo Tampere" in a lesser frequency.

Most popular intervention types in "Terveystalo Tampere" are "Drug" (12 trials), "Device" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Abrocitinib 200 mg" (2 trials), "BMS-986165" (2 trials), "Crenezumab" (2 trials) and "Eptinezumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Terveystalo Tampere" are 18 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Terveystalo Tampere". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Terveystalo Tampere, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Terveystalo Tampere, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".